1-5 of 5
Mechthild Jonas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity

Ryan A. Heiser, Anthony T. Cao, Weiping Zeng, Michelle Ulrich, Patrick Younan, Martha E. Anderson, Esther S. Trueblood, Mechthild Jonas, Robert Thurman, Che-Leung Law, Shyra J. Gardai
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (1): 68–83.
https://doi.org/10.1158/1535-7163.MCT-23-0118
Published: 03 January 2024
View article titled, Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Open the PDF for Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity in another window
Includes: Supplementary data
Journal Articles

SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications

Robert P. Lyon, Mechthild Jonas, Christopher Frantz, Esther S. Trueblood, Roma Yumul, Lori Westendorf, Christopher J. Hale, Jackie L. Stilwell, Narayana Yeddula, Katie M. Snead, Vineet Kumar, Gabriela I. Patilea-Vrana, Kerry Klussman, Maureen C. Ryan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12): 1444–1453.
https://doi.org/10.1158/1535-7163.MCT-22-0817
Published: 01 December 2023
View article titled, SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Open the PDF for SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications in another window
Includes: Supplementary data
Journal Articles

Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia

Fu Li, May Kung Sutherland, Changpu Yu, Roland B. Walter, Lori Westendorf, John Valliere-Douglass, Lucy Pan, Ashley Cronkite, Django Sussman, Kerry Klussman, Michelle Ulrich, Martha E. Anderson, Ivan J. Stone, Weiping Zeng, Mechthild Jonas, Timothy S. Lewis, Maitrayee Goswami, Sa A. Wang, Peter D. Senter, Che-Leung Law, Eric J. Feldman, Dennis R. Benjamin
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (2): 554–564.
https://doi.org/10.1158/1535-7163.MCT-17-0742
Published: 01 February 2018
View article titled, Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia
Open the PDF for Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates

Fu Li, Michelle Ulrich, Mechthild Jonas, Ivan J. Stone, Germein Linares, Xinqun Zhang, Lori Westendorf, Dennis R. Benjamin, Che-Leung Law
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (7): 1347–1354.
https://doi.org/10.1158/1535-7163.MCT-17-0019
Published: 04 July 2017
View article titled, Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates
Open the PDF for Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates in another window
Includes: Supplementary data
Journal Articles

Humanized anti-CD19 auristatin antibody-drug conjugates display potent antitumor activity in preclinical models of B-cell malignancies

Hans-Peter Gerber, Carol Morris-Tilden, Ivan Stone, Mechthild Jonas, May Kung-Sutherland, Jamie Miyamoto, Lindsay Brown, Lori Westendorf, Damon Meyer, Django Sussman, Paul Carter, Che-Leung Law, Iqbal Grewal
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B60.
Published: 01 November 2007
View article titled, Humanized anti-CD19 auristatin antibody-drug conjugates display potent antitumor activity in preclinical models of B-cell malignancies